<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414852</url>
  </required_header>
  <id_info>
    <org_study_id>HR-APTN-I-011</org_study_id>
    <nct_id>NCT04414852</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function</brief_title>
  <official_title>A Multi-center, Non-randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetics of Apatinib Mesylate in Subjects With Impaired Renal Function and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects&#xD;
      with impaired renal function and healthy subjects, to give dose recommendations for patients&#xD;
      with impaired renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 5, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-96 hours</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0-96 hours</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to 96h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>0-96 hours</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to infinity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Subjects With Impaired Renal Function and Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate remal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>normal renal impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>All the subjects will be administrated with 250mg apatinib on day 1</description>
    <arm_group_label>mild renal impairment</arm_group_label>
    <arm_group_label>moderate remal impairment</arm_group_label>
    <arm_group_label>normal renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        for subjects with impaired renal function&#xD;
&#xD;
          -  Able to comprehend and willing to sign an informed consent form (ICF)&#xD;
&#xD;
          -  18-70 years of age.&#xD;
&#xD;
          -  19 kg/m2&lt;BMI &lt;19-28 kg/m2&#xD;
&#xD;
          -  eGFR (MDRD equation) for mild impaired renal function: 60-89 mL/min/1.73 m2 eGFR (MDRD&#xD;
             equation) for moderate impaired renal function: 30-59 mL/min/1.73 m2&#xD;
&#xD;
          -  In good health, except for kidney disease and complications, determined by no&#xD;
             clinically significant findings from medical history, physical examination, 12-lead&#xD;
             ECG;&#xD;
&#xD;
          -  Agree to take approved method of contraception during the clinical trail and 8 weeks&#xD;
             after the last dose of apatinib. Female subject should be negative in the pregnancy&#xD;
             test;&#xD;
&#xD;
        for healthy subjects:&#xD;
&#xD;
          -  Able to comprehend and willing to sign an informed consent form (ICF)&#xD;
&#xD;
          -  18-70 years of age.&#xD;
&#xD;
          -  19 kg/m2&lt;BMI &lt;19-28 kg/m2&#xD;
&#xD;
          -  eGFR (MDRD equation) for mild impaired renal function: ≥90mL/min/1.73 m2&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG;&#xD;
&#xD;
          -  Agree to take approved method of contraception during the clinical trail and 8 weeks&#xD;
             after the last dose of apatinib. Female subject should be negative in the pregnancy&#xD;
             test;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        for subjects with renal impairment&#xD;
&#xD;
          -  Renal allograft recipients;&#xD;
&#xD;
          -  Need hemodialysis during study;&#xD;
&#xD;
          -  Uroclepsia or anuria;&#xD;
&#xD;
          -  Allergic to apatinib or ingredients;&#xD;
&#xD;
          -  History of heart disease in 12 months before study;&#xD;
&#xD;
          -  Coagulation disorders;&#xD;
&#xD;
          -  Hypertension and could not be controlled with hypotensor;&#xD;
&#xD;
          -  With hepatic or archenteric disease;&#xD;
&#xD;
          -  Participate in blood donation within 3 months before screening and donate blood volume&#xD;
             ≥400mL, or receive blood transfusion, or donate blood volume≥200mL within 1 month&#xD;
             prior dosing.&#xD;
&#xD;
          -  Take any clinical trial drugs within 3 months prior dosing;&#xD;
&#xD;
          -  Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A in 14 days&#xD;
             before dosing;&#xD;
&#xD;
          -  Addicted to alcohol and tobacco, drinking 14 units of alcohol per week (1 unit = 285&#xD;
             mL of beer, or 100mL of wine), or take ≥5 cigarettes;&#xD;
&#xD;
          -  Positive in urine drug test;&#xD;
&#xD;
          -  Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or&#xD;
             combined with syphilis infection;&#xD;
&#xD;
          -  Anyone who refuse to stop ingesting drinks containing methylxanthine, or grapefruit or&#xD;
             grapefruit-containing products from 48 hours before dosing to the end of the study;&#xD;
&#xD;
          -  The investigator believes that the subjects are not eligible to participate in this&#xD;
             trial.&#xD;
&#xD;
        for healthy subjects:&#xD;
&#xD;
          -  Renal allograft recipients;&#xD;
&#xD;
          -  Allergic to apatinib or ingredients;&#xD;
&#xD;
          -  History of heart disease in 12 months before study;&#xD;
&#xD;
          -  Coagulation disorders;&#xD;
&#xD;
          -  Hypertension and could not be controlled with hypotensor;&#xD;
&#xD;
          -  With hepatic or archenteric disease;&#xD;
&#xD;
          -  Participate in blood donation within 3 months before screening and donate blood volume&#xD;
             ≥400mL, or receive blood transfusion, or donate blood volume≥200mL within 1 month&#xD;
             prior dosing.&#xD;
&#xD;
          -  Take any clinical trial drugs within 3 months prior dosing;&#xD;
&#xD;
          -  Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A in 14 days&#xD;
             before dosing;&#xD;
&#xD;
          -  Addicted to alcohol and tobacco, drinking 14 units of alcohol per week (1 unit =285 mL&#xD;
             of beer, or 100mL of wine), or take ≥5 cigarettes;&#xD;
&#xD;
          -  Positive in urine drug test;&#xD;
&#xD;
          -  Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or&#xD;
             combined with syphilis infection;&#xD;
&#xD;
          -  Anyone who refuse to stop ingesting drinks containing methylxanthine, or grapefruit or&#xD;
             grapefruit-containing products from 48 hours before dosing to the end of the study;&#xD;
&#xD;
          -  The investigator believes that the subjects are not eligible to participate in this&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuya Wang</last_name>
    <phone>13918749176</phone>
    <email>wangyuya@hrglobe.cn</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

